Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (851 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: leukemiaamlmdscarcinomaacute
  Phrases that lowered it: patientsmgaminotransferaseinterfere withsigns
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Drug's FAERS reports with a death: 32.5% (raises risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 23 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Minimum age: 60 (raises risk) · Who can join
• Sponsor's past trials: 78 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Keywords listed: 0 (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm NCT01101880 · started 2010 · scored riskier than 96% of active trials completed
• Oral Clofarabine for Acute Myeloid Leukemia NCT00727766 · started 2009 · scored riskier than 89% of active trials completed
• Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients NCT01003678 · started 2009 · scored riskier than 66% of active trials terminated
• PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias NCT01169012 · started 2010 · scored riskier than 92% of active trials completed
• A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS) NCT00750334 · started 2008 · scored riskier than 51% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.